Event Details
*Open to GOC Members only*
The CoP in Immunotherapy invites you to an upcoming webinar titled "A case-based discussion of the Canadian experience with Pembrolizumab/Lenvatinib in advanced endometrial cancer." Our panel of experts will guide you through the optimal management of patients receiving Pembrolizumab/Lenvatinib therapy.
During the webinar, our expert panel will cover key topics such as optimal baseline and on-treatment evaluation of patients on Pembrolizumab/Lenvatinib therapy, managing common toxicities including hypertension, hyperthyroidism, and diarrhea, and approaches to dose-modification and optimization.
The webinar is perfect for healthcare professionals, physicians, and nurses seeking to gain a deeper understanding of managing patients with advanced endometrial cancer. Our expert panel will share their clinical expertise and real-world experiences in managing patients receiving Pembrolizumab/Lenvatinib therapy.
Learning Objectives:
At the end of the webinar discussion, participants should have an understanding of:
1. Optimal baseline and on-treatment evaluation of pts on pembro/Lenvatinib
2. Approach to managing common toxicities: focus on HTN, hyperthyroidism, diarrhea
3. Approach to considering dose-modification/optimization
